CRISPR-T Trademark

Trademark Overview

On Wednesday, September 28, 2016, a trademark application was filed for CRISPR-T with the United States Patent and Trademark Office. The USPTO has given the CRISPR-T trademark a serial number of 87186072. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 9, 2019. This trademark is owned by KSQ Therapeutics, Inc.. The CRISPR-T trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery services; Laboratory research services relating to pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields
crispr-t

General Information

Serial Number87186072
Word MarkCRISPR-T
Filing DateWednesday, September 28, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 9, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 12, 2017

Trademark Statements

Goods and ServicesDrug discovery services; Laboratory research services relating to pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 3, 2016
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKSQ Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameKSQ Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, December 9, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 9, 2019ABANDONMENT - NO USE STATEMENT FILED
Friday, May 3, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 1, 2019EXTENSION 3 GRANTED
Wednesday, May 1, 2019EXTENSION 3 FILED
Wednesday, May 1, 2019TEAS EXTENSION RECEIVED
Tuesday, November 20, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, November 20, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, October 13, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 11, 2018EXTENSION 2 GRANTED
Thursday, October 11, 2018EXTENSION 2 FILED
Thursday, October 11, 2018TEAS EXTENSION RECEIVED
Saturday, May 5, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 3, 2018EXTENSION 1 GRANTED
Thursday, May 3, 2018EXTENSION 1 FILED
Thursday, May 3, 2018TEAS EXTENSION RECEIVED
Tuesday, November 7, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 12, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 12, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 23, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, July 29, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 28, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 27, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 27, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 12, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 12, 2017NON-FINAL ACTION E-MAILED
Thursday, January 12, 2017NON-FINAL ACTION WRITTEN
Thursday, January 5, 2017ASSIGNED TO EXAMINER
Monday, October 3, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, October 1, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

crispr research fields services pharmaceuticals genetics information pharmaceutical biotechnology development providing